Gmania

@BWalkerTTAGGG Hey Bill. What our your thoughts on the Cantor initiation of CADL also has your outlook changed. TY

Ah, apparently it was Cantor Fitzgerald's recommendation.

Judging by CADL's stock price, some mutual-fund manager finally got around to reading their Phase 3 trial results. Woohoo!

@oshea9_harry @CandelTx @paulpetertak @papa_spiegs Harry Thanks for your insight. Do you see anything with manufacturing being an issue.

@CandelTx @paulpetertak My grandmother would call this a money shot in the cantor deck. She loved the money shots, like @papa_spiegs who turned 88 today Candel did the work, completed a RCT, and took the time to sign a SPA with the FDA

We’re heading to #AUA2026 in Washington, D.C.! Join us for our presentation featuring the phase 3 trial of aglatimagene besadenovec in localized prostate cancer on May 15 at 11:30 AM and visit our booth. ir.candeltx.com/news-releases/… #ProstateCancer #Immunotherapy $CADL

@paulpetertak Dr PPT. Nice to Cantor Fitzgerald initiation of CADL.

@oshea9_harry It’s never too late to stop smoking!

Mapping Candel Therapeutics' Sprint To The BLA Finish Line bioprocessonline.com/doc/mapping-ca…

@oshea9_harry @AlienHocke16905 @paulpetertak @FahadThoughts97 You should share with the ST community

@AlienHocke16905 @paulpetertak @FahadThoughts97 I sent a few out to investors

Looking forward to Accelerating Bio-Innovation (ABI), Cambridge, England. abiconference.com Royalty Pharma, University of Cambridge

@paulpetertak Dr PPT. Here is some great news to start the week. Cantor Fitzgerald nice. tipranks.com/news/the-fly/c…

@paulpetertak Dr PPT. GREAT WORK. Have a nice weekend.

Stories like this remind us why we do what we do: parade.com/health/kyle-do… The journey of Kyle Donahue, featured in Parade, is both deeply personal and scientifically meaningful. Diagnosed with recurrent glioblastoma and initially given only months to live, she is now a five-year survivor after participating in a clinical trial of linoserpaturev (CAN-3110). Clinical trials are where hope meets science. For a disease where median survival is typically measured in months and long-term survival remains rare, such outcomes are extraordinary, and instructive. What stands out is not only the individual story, but what it represents: The potential of viral immunotherapy to reshape the tumor microenvironment. The importance of activating the immune system in ways that may lead to durable responses. And critically, the indispensable role of patients who choose to participate in clinical trials. In glioblastoma, progress has been frustratingly slow for decades. But we are now seeing signals that suggest we may finally be turning a corner. We should be careful not to overinterpret early data. Yet we should be equally careful not to underestimate what these signals mean for patients and for the field.

@adamfeuerstein CADL thoughts?

Friends - My humble request is that you sign up for the email version of my weekly newsletter. Its contents are also posted on STAT's website, but the email arrives every Thursday at 6:30 am ET which means you can hate-read it over coffee. statnews.com/signup/scoreca…

@BIOTECHSCANNER Looking to get into IOVA. Do you happen to have any thoughts on CADL? Thanks.

$IOVA - Did you know Amtagvi (lifileucel) is a living drug? What’s that mean? Unlike 99% of drugs on the market that have something called “half-life” that determines how long it stays in the body and how frequently it needs to be dosed, Amtagvi contains the patient’s own living T-cells. These T-cells live and fight cancer as long as the patient is still alive. Amtagvi doesn’t have a half life!!! There have been patients who got a partial response (PR) from Amtagvi and 3 years later turned into a complete response (CR). THERE IS NO DRUGS CURRENTLY ON THE MARKET THAT CAN DO THIS. NONE. The market will reward Iovance handsomely. The cream always rises to the top in pharmaceuticals. The best treatment will always be recognized. I predicted that Mounjaro would become the new GLP-1 market leader a year ago and that’s exactly what happened. I said this when Mounjaro was still relatively unknown! This is what 19 years of pharmaceutical industry experience gives me. I am telling you right now, that Iovance will be a $30B company if not bought out sooner. It will be bought. It’s not if but when. I think it’s going to happen in 2nd half of 2027. $4 is still the bottom. So as $5 and $6.

@CandelTx @paulpetertak Dr. PPT. Anything you might be able to say to investors regarding CADL current market cap and also why there is a high short interest. Thanks for your time.

Extended follow-up data from our phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer will be presented at #AUA2026 in Washington, D.C. ir.candeltx.com/news-releases/… @AmerUrological #AUA2026 #ProstateCancer #Immunotherapy $CADL

@oshea9_harry @paulpetertak Lol. Love it. One more question. What's going to be bigger CADL or IBRX?

@Gmania99 @paulpetertak Oh yeah it’s Tak

Today we reported our fourth quarter and full-year 2025 financial results and recent corporate highlights at Candel Therapeutics. Over the past year, our team continued to advance our mission of developing multimodal viral immunotherapies designed to help patients fight cancer. We made important progress across our clinical programs while strengthening the foundation for future growth and potential commercialization. Key highlights include: 1. Continued progress toward a potential BLA submission for CAN-2409 in localized prostate cancer 2. Advancement of our broader pipeline, including CAN-3110 in recurrent high-grade glioma 3. Strategic financing initiatives that strengthen our balance sheet and support future development 4. We remain focused on translating compelling science into meaningful therapies for patients with serious cancers. I am grateful to the patients, investigators, employees, and partners who make this progress possible. globenewswire.com/news-release/2…

@oshea9_harry @paulpetertak TY. Who is that pictured on your T Shirts? Doesn't look like PPT

@Gmania99 @paulpetertak I continue to accumulate

@oshea9_harry @paulpetertak Harry wondered your thoughts on the recent stock price action

@paulpetertak Still looking for non dilutive funding for PDAC?

@CandelTx @paulpetertak @cure_today Can you get this incredible story to the national media?

This @cure_today article explores linoserpaturev (CAN-3110), our viral immunotherapy candidate for recurrent glioblastoma, through the story of Kyle Donahue, a five-year survivor. curetoday.com/view/given-mon… #Glioblastoma #Immunotherapy

@DrMakaryFDA CADL Candel Therapeutics. Keep an eye on it.

Treating patients with rare diseases has an impact on your soul. That's why we're moving fast.

@paulpetertak Dr PPT. I would like to start off by apologizing for my bitter post lately. I truly am sorry. I let my frustration get the best of me. Can I ask you what you and your team think is going to be Candel's biggest asset? Thanks to you and your team for all the hard work.

Last day of ask me anything on top of a busy job. Need to catch up on sleep. Thank you all for the great questions.

@oshea9_harry @paulpetertak Thanks, Harry. Appreciate all your time and effort. Holding a large position here. Also a Wegmans fan born in Rochester NY so I grew up with Wegmans.

@Gmania99 @paulpetertak Walk through that grok exchange I half assed it but I’m busy

$CADL Ask me anything

@oshea9_harry @paulpetertak Harry, how confident are you on CADL being successful

@RouteCO145 @paulpetertak Dude, i don’t want Tak wearing an orange jumpsuit, do you? Really not his color… winter greens & blues work better. Accents his eyes & Dutchness. human equivalent of a really long IKEA shell, tall, formerly blonde, structurally sound, occasionally blocking views at concerts

@paulpetertak @CandelTx @PharmaVoice TY. One last question. Do you think the newly granted stock options priced at 6.01 over the next 4 years, going to keep a cap on the sp.

@Gmania99 @CandelTx @PharmaVoice We gave a very detailed update on Virtual R&D Day in December. It can be viewed online via candeltx.com

Thank you to @PharmaVoice for including our CEO @paulpetertak among industry leaders sharing their outlook for pharma in 2026. Dr. Tak shares his perspective on why adaptability will define successful commercialization strategies moving forward. pharmavoice.com/news/pharma-cr…

@CandelTx @paulpetertak Nice article. finance.yahoo.com/news/oncolytic…

This #WorldCancerDay, our commitment remains clear: developing innovative immunotherapies that harness each patient’s own immune system to fight cancer. We’re advancing two clinical-stage immunotherapy platforms targeting some of cancer’s toughest challenges.